To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require health insurance issuers and MA organizations to make publicly available certain information with respect to coverage request rejection.
Summary
HR10024, introduced in the House and referred to Energy and Commerce and Ways and Means, would require health insurers and Medicare Advantage organizations to publicly disclose coverage request rejection information. This early-stage transparency bill imposes compliance costs and reputational risk on major insurers like UNH, HUM, CVS, and CI, but has no direct funding or immediate revenue impact. The market impact is limited to administrative burden and potential public scrutiny of denial rates.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10024 is a low-impact transparency bill that imposes compliance costs on health insurers but no direct funding.
- 2.Medicare Advantage-focused insurers like UNH and HUM are most exposed to the disclosure requirement.
- 3.The bill is in early stage with no cosponsors, making passage unlikely in the current session.
Market Implications
The bill's introduction is unlikely to move stock prices materially. For $UNH, with $371.6B revenue, incremental compliance costs are trivial. For $HUM, which is more concentrated in MA, the impact is relatively larger but still not transformative. Any sell-off would be shallow and short-lived. Investors should monitor whether the bill gains committee traction or cosponsors—if it does, the regulatory risk to MA insurers could rise, but current odds are low.
Full Analysis
-
What happened: On August 3, 2026, Rep. Hinson (R-IA) introduced HR10024, which amends the Public Health Service Act and Social Security Act to require health insurance issuers and Medicare Advantage organizations to make publicly available information about coverage request rejections. The bill was referred to the Energy and Commerce and Ways and Means committees. It is at the earliest legislative stage with no cosponsors and no committee action yet.
-
The money trail: This bill authorizes no funding. It is a regulatory mandate on private insurers, not a spending program. The cost to insurers is administrative—implementing systems to compile and publish rejection data. There is no appropriation involved, so the federal government spends nothing directly. The financial impact is a compliance cost on affected companies, which is likely to be modest relative to their revenue bases.
-
Convergence: No related signals or procurement data were provided. This is an isolated transparency bill. However, it aligns with a broader regulatory trend of increasing healthcare pricing and coverage transparency, though no specific White House action or companion bill is present. The absence of convergence means the bill should be analyzed on its own merits.
-
Structural winners and losers: The clear losers are Medicare Advantage insurers that will face new disclosure requirements. UNH, HUM, CVS (Aetna), and CI are the public pure-plays or major players in this space. The bill does not create any winners—consumers may benefit from transparency, but no public company is directly advantaged. The impact is a mild negative administrative burden and potential reputational risk.
-
Timeline: The bill is in early stages. It will need committee hearings, markup, and a floor vote in the House, then Senate passage and presidential action. Given the 119th Congress is halfway through (2026), the probability of enactment in this session is low. Most similar transparency bills stall. If it does pass, implementation would occur after a rulemaking period, likely 1-2 years after enactment.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Mandates public disclosure of coverage request rejection information for health insurers and Medicare Advantage organizations
Who must act
UnitedHealthcare's Medicare Advantage plans and all health insurance issuers
What happens
Increased administrative costs for data collection and publication, plus potential reputational risk from public scrutiny of rejection rates
Stock impact
UnitedHealth Group's UnitedHealthcare segment is the largest Medicare Advantage provider in the US; compliance will require system changes and reporting processes, and public rejection-rate data could affect member enrollment and employer/client relationships. The company's $371.6B revenue base means incremental compliance costs are immaterial, but reputational exposure is real.
What the bill does
Mandates public disclosure of coverage request rejection information for Medicare Advantage organizations
Who must act
Humana's Medicare Advantage plans
What happens
Higher compliance costs and potential member backlash if rejection rates are unfavorable; Humana's business is heavily MA-focused so this is more material than for diversified insurers
Stock impact
Humana derives the majority of its revenue from Medicare Advantage; the disclosure requirement directly affects its core product line, raising administrative spend and potentially impacting star ratings and enrollment. Though Humana's exact revenue is not provided, it is a pure-play MA insurer, so this is a direct regulatory burden.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Improving Seniors’ Timely Access to Care Act of 2025
Great American Healthcare Plan
PBM Act
January 6th Law Enforcement Heroes Compensation Fund Act
Protecting Seniors and Stopping Fraudsters Act
Access to Genetic Counselor Services Act of 2025
HELP Copays Act
PBM Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →